Research programme: chimeric antigen receptor T cell therapeutics - MabVax/MSKCC

Drug Profile

Research programme: chimeric antigen receptor T cell therapeutics - MabVax/MSKCC

Alternative Names: CAR T-cell therapeutics - MabVax/MSKCC; CART cell therapies - MabVax/MSKCC

Latest Information Update: 15 Jun 2017

Price : $50

At a glance

  • Originator MabVax Therapeutics; Memorial Sloan-Kettering Cancer Center
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Immunostimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Solid tumours

Most Recent Events

  • 31 May 2017 MabVax Therapeutics enters into a research agreement with Memorial Sloan Kettering Cancer Center for Pancreatic cancer, Small cell lung cancer and other Solid tumours
  • 10 Sep 2014 Early research in Solid tumours in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top